Company: ARWR
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001628280-25-038858
Chunk: 17

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 17
---
 — — — 1,512 Common stock - restricted stock units vesting723 1 (1)— — — — Common stock issued, net of offering costs15,790 16 429,249 — — — 429,265 Foreign currency translation adjustments— — — (56)— — (56)Unrealized gains on available-for-sale securities— — — 216 — — 216 Net loss— — — — (125,300)(1,696)(126,996)Balance at March 31, 2024124,133 $217 $1,768,866 $(1,095)$(1,284,194)$11,611 $495,405 Stock-based compensation— — 17,050 — — — 17,050 Exercise of stock options43 — 388 — — — 388 Common stock - restricted stock units vesting51 — — — — — — Foreign currency translation adjustments— — — (141)— — (141)Unrealized gains on available-for-sale securities— — — 249 — — 249 Net loss— — — — (170,793)(3,184)(173,977)Balance at June 30, 2024124,227 $217 $1,786,304 $(987)$(1,454,987)$8,427 $338,974 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

3

Arrowhead Pharmaceuticals, Inc.

Consolidated Statements of Cash Flows 

(in thousands)

(unaudited)

Nine Months Ended June 30,20252024CASH FLOWS FROM OPERATING ACTIVITIES:Net income (loss)$13,993 $(436,349)Adjustments to reconcile net income (loss) to net cash flow from operating activitiesStock-based compensation44,279 54,494 Depreciation and amortization17,542 13,570 (Accretion) amortization of note premiums/discounts(4,545)7,886 Realized loss on investments— (80)Non-cash interest expense on liability related to the sale of future royalties18,893 17,705 Non-cash